Shmuel Yaccoby, PhD

Full Member

Research Program:

Cancer Biology

Faculty Rank:

Professor

Campus:

University of Arkansas for Medical Sciences

College:

College of Medicine

Department:

Internal Medicine

Cancer Research Interest

Disease Site Focus: Multiple Myeloma
Research Focus Area: Health Disparities, Prevention, Treatment, Informatics, Detection, Diagnosis/ Prognosis
Type of Research: Basic
Research Interest Statement: Pathogenesis of multiple myeloma, tumor microenvironment, bone marrow mesenchymal stem cells, and tumor initiating cells.

US Department of Defense – W81XWH2110601
“Role of novel myeloma subpopulations in the disease progression and drug resistance”
Principal Investigator
09/30/21 – 09/29/24

Ling W, Johnson SK, Mehdi SJ, [et al., including Yaccoby S]. EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression. Cancers. 2023 15(18). PMID: 37760488. PMCID: PMC10526862.
Mehdi SJ, Ghatak K, Ling W, [et al., including Yaccoby S]. Growth and dormancy control of myeloma cells by mesenchymal stem cells. Leukemia research. 2023 133:107355. PMID: 37499483.
Mikulasova A, Kent D, Trevisan-Herraz M, [et al., including Yaccoby S]. Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome research. 2021. PMID: 34933939. PMCID: PMC9341503.
Schinke CD, Boerma M, Bird JT, [et al., including Yaccoby S]. PHF19 inhibition as a therapeutic target in multiple myeloma. Current research in translational medicine. 2021 69(3):103290. PMID: 33894670. PMCID: PMC8316274.
Mikulasova A, Ashby C, Tytarenko RG, [et al., including Yaccoby S]. Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma. Haematologica. 2019. PMID: 31221783. PMCID: PMC7109748.